Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encorafenib + cetuximab + pembrolizumab versus pembrolizumab in untreated BRAF V600E-mutant MSI-H/dMMR metastatic colorectal cancer
NL-OMON56187Phase 2Not yet recruiting
- Sponsor
- Pfizer
- Start
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of encorafenib, cetuximab and pembrolizumab in colorectal cancer (CRC) (2 arms), sponsored by Pfizer. Primary endpoint: Progression-free survival. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON56187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56187.